RT Journal Article SR Electronic T1 Exposure to attention deficit hyperactivity disorder medications during pregnancy JF Canadian Family Physician JO Can Fam Physician FD The College of Family Physicians of Canada SP 1153 OP 1155 VO 53 IS 7 A1 Caitlin Humphreys A1 Facundo Garcia-Bournissen A1 Shinya Ito A1 Gideon Koren YR 2007 UL http://www.cfp.ca/content/53/7/1153.abstract AB QUESTION An 18-year-old patient of mine, currently under treatment for attention deficit hyperactivity disorder (ADHD) with methylphenidate, just found out that she is pregnant. What are the risks for the baby when the mother uses ADHD medications during pregnancy? ANSWER Available evidence for amphetamines suggests no increased risk of malformations with use of therapeutic doses, and inadvertent exposure during pregnancy is unlikely to be harmful. Human data for methylphenidate and atomoxetine treatment in pregnancy are very limited. Documented cases do not suggest teratogenicity, but we cannot rule out this risk with the information available.